PD-L1 expression is associated with an increased objective response rate to therapy, with better responses observed when the CPS ≥ 20, as was recently shown in clinical trials investigating the efficacy of this first-line immune checkpoint inhibitor in recurrent and/or metastatic HNSCC (Burtness et al., 2019). Here, CD274 is linked to head and neck squamous cell carcinoma.